Skip to main content
. Author manuscript; available in PMC: 2018 Jan 15.
Published in final edited form as: Clin Cancer Res. 2017 Feb 6;23(14):3552–3556. doi: 10.1158/1078-0432.CCR-16-2064

Table 7. Response by CTCL Subtype.

CTCL Subtype ORR CR PR
All evaluable patients (N=33)* 20 (61%) 4 (12%) 16 (48%)
MF (n=19) 12 (63%) 2 (11%) 10 (53%)
Transformed MF (n=10) 5 (50%) 1 (10%) 4 (40%)
Sézary syndrome (n=3) 2 (67%) 0 (0) 2 (67%)
ALCL (n=1) 1 (100%) 1 (100%) 0 (0)
Stage of MF Responders IIB, IVA2(2) t-IA;IB(3);IIa (3); IIb(7); & III;IVA1;IVB (1)
a

Included all patients who received at least 1 dose of pralatrexate or bexarotene and had a baseline response evaluation t = transformed